Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
EyePoint Pharmaceuticals ( (EYPT) ) just unveiled an update.
On July 29, 2025, EyePoint Pharmaceuticals announced the completion of enrollment for its Phase 3 pivotal trials, LUGANO and LUCIA, evaluating DURAVYU for wet AMD. The trials enrolled over 800 patients, marking one of the fastest enrollments for such programs. Interim safety data confirmed DURAVYU’s favorable safety profile, with no serious adverse events related to the drug. The trials are designed to support regulatory approval and aim to reduce treatment burden with a 6-month redosing schedule, potentially shifting the treatment paradigm for wet AMD.
The most recent analyst rating on (EYPT) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on EyePoint Pharmaceuticals stock, see the EYPT Stock Forecast page.
Spark’s Take on EYPT Stock
According to Spark, TipRanks’ AI Analyst, EYPT is a Neutral.
The overall score reflects the company’s strong technical momentum and positive corporate developments, which are moderated by financial performance challenges and valuation concerns. The positive sentiment from the earnings call further supports the stock’s outlook, though profitability and cash flow management remain key risks.
To see Spark’s full report on EYPT stock, click here.
More about EyePoint Pharmaceuticals
EyePoint Pharmaceuticals, Inc. is a company focused on developing and commercializing innovative therapeutics for serious retinal diseases. Their primary product, DURAVYU, is a sustained-delivery treatment for VEGF-mediated retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
Average Trading Volume: 789,038
Technical Sentiment Signal: Buy
Current Market Cap: $690.2M
Find detailed analytics on EYPT stock on TipRanks’ Stock Analysis page.